Innovent Biologics (Suzhou) Co. Ltd.

Biotech

Suzhou, Jiangsu, China · Est. 2011

Innovent Biologics is a biopharmaceutical company focused on developing innovative monoclonal antibody therapies for cancer, autoimmune, and infectious diseases.

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

178

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

11 drugs in development

Approved1

Phase 34

Phase 24

Phase 15

By Therapeutic Area

top 6

Oncology

635%

Ophthalmology

212%

Metabolic & Endocrine

212%

Respiratory

212%

Immunology

212%

Gastroenterology

16%

R&D Momentum

72/100

Pipeline Velocity

46/100

Trial Completion Rate

82/100

Pipeline Concentration

19/100

Pipeline Freshness

78/100

Strategic Signals

↗Active in Ophthalmology but thin pipeline — potential licensing opportunity

Activity

Key Events

Jun 25, 2026TrialA Phase 1/2 Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Apr 1, 2026TrialIBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia

Apr 1, 2026TrialEfficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity

Mar 30, 2026TrialIBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Mar 25, 2026TrialIBI343 in Combination Therapy for Advanced Malignant Solid Tumors

Mar 24, 2026TrialA Mutiple-dose Study of IBI3033 in Healthy Participants

Feb 6, 2026TrialA Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis

Feb 6, 2026TrialA Dose Finding Study of IBI3016 in Mild to Moderate Hypertensive Patients

4 more events

Feb 4, 2026TrialIBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer

Dec 31, 2025TrialA Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis

Dec 30, 2025TrialA Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease

Dec 29, 2025TrialA Study of IBI362 in Chinese Adolescents With Obesity or Overweight

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

CEODe-an Gao

Founded2011

HQSuzhou, Jiangsu, China

Websiteinnoventbio.com

LinkedInCompany Page

Therapeutic Focus

OncologyImmunologyAutoimmune diseases

Patent Expirations

2 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Dexedrine Spansule2 patentsOct 24, 2033 Dexedrine SpansuleJan 6, 2042

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Gastroenterology(1 drug)

—

Gastroenterology(1 drug)

Immunology(2 drugs)

—

Immunology(2 drugs)

Infectious Disease(1 drug)

—

Infectious Disease(1 drug)

Metabolic & Endocrine(2 drugs)

—

Metabolic & Endocrine(2 drugs)

Oncology(6 drugs)

—

Oncology(6 drugs)

Ophthalmology(2 drugs)

—

Ophthalmology(2 drugs)

Respiratory(2 drugs)

—

Respiratory(2 drugs)

Unknown / Other(1 drug)

—

Unknown / Other(1 drug)

Regulatory

Regulatory Timeline

19821 event

FDAJan 1

Dexedrine Spansule — DEXEDRINE SPANSULE

Application NDA017078 (NDA)

20221 event

FDAMar 22

Dexedrine Spansule — XELSTRYM

Application NDA215401 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)